Palociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase
Martin, M., et al. Palociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase. Annals of Oncology, Volume 32, Issue 4, April 2021, Pages 427-430
- Categories
- Peer Reviewed Publications